Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
Not yet recruiting · NCT07745257 · Registry updated 2026-08-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases | HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases | Not yet recruiting | Phase 2 | 2026-08-04 | NCT07745257 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sun Yat-sen University | 606 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Anyang Tumor Hospital | Anyang | China | 10 |
| Henan Cancer Hospital | Zhengzhou | China | 67 |
| Nanchang People's Hospital | Nanchang | China | 4 |
| Nanjing Drum Tower Hospital | Nanjing | China | 52 |
| Sichuan Provincial People's Hospital | Chengdu | China | 50 |
| Sun Yat-sen University Cancer Center | Guangzhou | China | 315 |
| The Fourth Hospital of Hebei Medical University | Shijiazhuang | China | 30 |
| The Second Affiliated Hospital of Dalian Medical University | Dalian | China | 2 |
| Zhejiang Cancer Hospital | Hangzhou | China | 164 |